Goodbye oral iron therapy?

Pediatric Blood and Cancer

Volumn 60, Issue 11, 2013, Pages 1731-1731

  Forman, Edwin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON DEXTRAN;

ARTICLE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; MEAN CORPUSCULAR VOLUME; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANEMIA, IRON-DEFICIENCY; FEMALE; HEMATINICS; HUMANS; IRON-DEXTRAN COMPLEX; MALE;

EID: 84883773096     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24710     Document Type: Article

References (6)

1. Plummer E, Crary S, McCavit T, et al. Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. Pediatr Blood Cancer 2013.
2. Cray SE, Hall K, Buchanan GR. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. Pediatr Blood Cancer 2011; 56:615-619.
3. Auerbach M, Pappadakis JA, Bahrain H, et al. Safety and efficacy of rapid administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011; 86:860-862.
4. Auerbach M, Ballard H. Clinical use of intravenous iron: Administration, efficacy, and safety. Hematol Am Soc Hematol Educ Program 2010; 2010:338-347.
5. Okam MM, Mandell E, Hevelone N, et al. Comparative rates of adverse events with different formulations of intravenous iron. Am Hematol 2012; 87:E123-E124.
6. Auerbach M. Should intravenous iron be upfront therapy for iron deficiency anemia? Pediatr Blood Cancer 2011; 56:511-512.